Tumour immunotherapy: the adjuvant treatment of the 21st century?

被引:11
作者
Bremers, AJA
Kuppen, PJK
Parmiani, G
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[2] Ist Nazl Tumori, Unit Human Tumour Immunotherapy, I-20133 Milan, Italy
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2000年 / 26卷 / 04期
关键词
neoplasms; immunotherapy; neoplasm antigen;
D O I
10.1053/ejso.1999.0908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the course of a century, tumour immunology has revealed a picture of a very complex immune system involving the recognition and eradication of malignancies. Many tumours evade the immune system, and understanding of tumour escape mechanisms is the key to a successful immunotherapy for cancer. A wide array of tumour immunotherapy modalities have been developed, many of which have reached the phase of clinical trials, with some satisfactory results. Based on the available clinical, data and the techniques available for further improvement, we analyse the prospects for the different treatment modalities, and predict an important role for tumour immunotherapy in the near future. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:418 / 424
页数:7
相关论文
共 92 条
[1]   Adjuvant interferon treatment for melanoma [J].
Agarwala, SS ;
Kirkwood, JM .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1998, 12 (04) :823-+
[2]  
Anichini A, 1996, J IMMUNOL, V156, P208
[3]   ADOPTIVE IMMUNOTHERAPY OF ADVANCED MELANOMA PATIENTS WITH INTERLEUKIN-2 (IL-2) AND TUMOR-INFILTRATING LYMPHOCYTES SELECTED INVITRO WITH LOW-DOSES OF IL-2 [J].
ARIENTI, F ;
BELLI, F ;
RIVOLTINI, L ;
GAMBACORTIPASSERINI, C ;
FURLAN, L ;
MASCHERONI, L ;
PRADA, A ;
RIZZI, M ;
MARCHESI, E ;
VAGLINI, M ;
PARMIANI, G ;
CASCINELLI, N .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (05) :315-322
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]  
Bear HD, 1996, SEMIN SURG ONCOL, V12, P436
[6]  
BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[7]   Immunotherapy for colon cancer [J].
Bremers, AJA ;
Parmiani, G .
LANCET, 1999, 353 (9163) :1524-1525
[8]  
Brivio F, 1996, ONCOLOGY, V53, P263
[9]   Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: Clinical results and immunologic correlates of response [J].
Bukowski, RM ;
Olencki, T ;
Wang, Q ;
Peereboom, D ;
Budd, GT ;
Elson, P ;
Sandstrom, K ;
Tuason, L ;
Rayman, P ;
Tubbs, R ;
McLain, D ;
Klein, E ;
Novick, A ;
Finke, J .
JOURNAL OF IMMUNOTHERAPY, 1997, 20 (04) :301-311
[10]  
BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1